

REVIEW

# Vitamin D modulation of innate immune responses to respiratory viral infections

Mihnea T. Zdrengea<sup>1†</sup> | Heidi Makrinioti<sup>2†</sup> | Cristina Bagacean<sup>1,3</sup> | Andy Bush<sup>4†</sup> | Sebastian L. Johnston<sup>2†</sup> | Luminita A. Stanciu<sup>1,2†</sup>

<sup>1</sup>Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj and Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania

<sup>2</sup>Airways Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, UK

<sup>3</sup>Laboratory of Immunology and Immunotherapy, University Hospital Brest, France

<sup>4</sup>Department of Paediatric Respiratory Medicine, Royal Brompton Hospital and Imperial College London, London, UK

## Correspondence

M. T. Zdrengea, Iuliu Hatieganu University of Medicine and Pharmacy, Babeş Str. 8, 400124 Cluj-Napoca, Romania.  
Email: mzdrengea@umfcluj.ro

## Summary

Vitamin D, in addition to its classical functions in bone homeostasis, has a modulatory and regulatory role in multiple processes, including host defense, inflammation, immunity, and epithelial repair. Patients with respiratory disease are frequently deficient in vitamin D, implying that supplementation might provide significant benefit to these patients. Respiratory viral infections are common and are the main trigger of acute exacerbations and hospitalization in children and adults with asthma and other airways diseases. Respiratory monocytes/macrophages and epithelial cells constitutively express the vitamin D receptor. Vitamin D, acting through this receptor, may be important in protection against respiratory infections. Whether the in vitro findings can be translated into a substantial in vivo benefit still remains uncertain. Here we review the in vitro data on the role of vitamin D in antiviral innate immunity, the data concerning the deficient levels of vitamin D in lung diseases, and the in vivo role of supplementation as protection against respiratory viral infections in healthy individuals and in patients with chronic respiratory diseases. Finally, we suggest ways of improving the effectiveness of vitamin D as an adjuvant in the prevention and treatment of acute respiratory infections.

## KEYWORDS

innate immunity, respiratory viruses, vitamin D

## 1 | INTRODUCTION

Respiratory infections are frequently associated with severe colds in healthy people, especially in children and senior people, and with asthma exacerbations. 1 $\alpha$ ,25-dihydroxyvitamin D, the immunologically active form of vitamin D, through interaction with its own receptor, has the capacity to mediate epithelial cell proliferation, differentiation, and apoptosis. Furthermore, vitamin D has been shown to increase the antiviral potential of immune cells during respiratory viral infections in vitro, inducing increased expression of antimicrobial peptides, such as cathelicidin and defensin, and innate interferons, which are an important component of the airway responses against viruses.

<sup>†</sup>These authors contributed equally to this paper.

**Abbreviations:** 1,25(OH)<sub>2</sub>D, 1 $\alpha$ ,25-dihydroxyvitamin D; 1 $\alpha$ (OH)ase/CYP27B1, 1 $\alpha$ -hydroxylase enzyme; LRTIs, lower respiratory tract infections; PBMcs, peripheral blood mononuclear cells; RTI, respiratory tract infection; TLRs, toll-like receptors; URTIs, upper respiratory tract infections; 24(OH)ase/CYP24A1, vitamin D-24-hydroxylase; VDR, vitamin D receptor

In an era of debate on the rational use of expensive medicines, particularly in countries with limited resources, the use of vitamin D as a strategy to reduce the frequency and severity of respiratory infections needs to be seriously considered. However, the current evidence of efficacy of vitamin D in preventing viral respiratory infections is inconsistent. There is a lack of prospective cohort studies with detailed vitamin D and immune profiling of the patients studied.

In this review we attempt to unveil the pathogenic mechanisms underlying vitamin D treatment during respiratory viral infections, as introduced by several in vitro and in vivo/ex vivo models that have been published so far. More importantly, in the second part of the review, we focus on translating these findings into a clinical perspective and, through reviewing currently published randomized clinical trials and cohort studies, we aim to conclude whether vitamin D supplementation has been identified as a promising adjuvant during common cold episodes or exacerbations of asthma or whether current and future vitamin D trials are a waste of funding, as recently highlighted in *BMJ*.<sup>1,2</sup>

For our review we have taken into consideration the recently published reviews (systematic or not) on the topic.<sup>3–5</sup> Our review aims

to combine both the clinical evidence and the “in vitro” evidence regarding the functional role of vitamin D during “common cold” episodes and cold-induced exacerbations of asthma, a subject not covered in the current reviews.

We hope that presenting the available published studies of vitamin D and respiratory viral infections, also contradictory, will help to improve the future clinical studies of efficacy of vitamin D supplementation in preventing viral infections in healthy persons and in asthma exacerbations.

## 2 | SYNTHESIS AND REGULATION OF METABOLISM OF VITAMIN D

The immunologically active form of vitamin D, 1 $\alpha$ ,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D, calcitriol) is formed through sequential hydroxylation. Vitamin D<sub>3</sub> (cholecalciferol) or vitamin D<sub>2</sub> (ergocalciferol) is hydroxylated by the cytochrome P450 enzyme 25-hydroxylase (CYP27A1), generating 25-hydroxyvitamin D (25(OH)D: 25(OH)D<sub>3</sub>, calcidiol, calcifediol, or 25(OH)D<sub>2</sub>). This form is a biologically inactive circulating metabolite but is subsequently hydroxylated intracellularly in the kidney or extrarenally, by the mitochondrial 1 $\alpha$ -hydroxylase enzyme (1 $\alpha$ (OH)ase/CYP27B1) into 1,25(OH)<sub>2</sub>D, the active form of calcitriol.<sup>6</sup>

25-hydroxyvitamin D levels are dependent on sun exposure and dietary intake of vitamin D, and serum levels are considered the most accurate marker for vitamin D status. Vitamin D levels over 20 ng/mL (50 nmol/L) are considered to be sufficient and  $\leq$ 20 ng/mL (50 nmol/L) insufficient.<sup>7,8</sup> The Endocrine Society has set the lower threshold of adequate 25(OH)D levels at 30 ng/mL (75 nmol/L).<sup>9</sup> These levels are based on maintaining bone health and are suggested also for lung diseases, although the optimal levels for immune health have yet to be established.

25-hydroxyvitamin D<sub>2</sub> binds to the carrier protein, vitamin D binding protein, with lower affinity than 25(OH)D<sub>3</sub>, which may facilitate bioavailability to immune cells such as monocytes.<sup>10</sup> Recently, it has been shown that many innate immune cells, including epithelial cells, monocytes/macrophages, and dendritic cells, can synthesize 1,25(OH)<sub>2</sub>D from 25(OH)D.<sup>6,11,12</sup> Extracellular 25(OH)D, bound to serum vitamin D binding protein, is endocytically internalized, and intracellularly synthesized 1,25(OH)<sub>2</sub>D will act on the nuclear vitamin D receptor (VDR).<sup>13</sup> 1 $\alpha$ ,25-dihydroxyvitamin D and its precursor 25(OH)D are catabolized by vitamin D-24-hydroxylase (24(OH)ase/CYP24A1).<sup>14</sup>

Cellular and serum concentrations of 1,25(OH)<sub>2</sub>D are regulated through a negative feedback loop.<sup>15</sup> Systemic levels of vitamin D are controlled via calcium and parathyroid hormone levels; however, local tissue production of 1,25(OH)<sub>2</sub>D is regulated by calcium-independent mechanisms, and higher levels of 1,25(OH)<sub>2</sub>D may be generated to activate innate immune responses.<sup>16</sup> There are data though supporting the view that intracellularly synthesized 1,25(OH)<sub>2</sub>D does not leak into the circulation and is degraded locally.

The autocrine and paracrine effects of 1,25(OH)<sub>2</sub>D are principally mediated through specific high-affinity VDR, referred to as “genomic” signaling and detected within hours of exposure to 1,25(OH)<sub>2</sub>D. 1 $\alpha$ ,25-Dihydroxyvitamin D transactivates target gene expression by binding to the nuclear VDR, and target genes can be either upregulated or downregulated depending on the coregulatory proteins involved

and the nature of the stimulus. 1 $\alpha$ ,25-dihydroxyvitamin D has the capacity to limit its own synthesis by exerting a negative feedback on the vitamin D signaling system,<sup>17</sup> decreasing CYP27B1 expression/1 $\alpha$ (OH)ase transcription and also increasing CYP24A1 with an increase in 24(OH)ase catabolic function (autocrine regulation).

In addition, rapid, nongenomic actions were reported for 1,25(OH)<sub>2</sub>D via a membrane receptor-associated, rapid response, steroid-binding protein and the nuclear VDR itself, and both membrane and nuclear receptor mediate rapid responses associated with cell proliferation, differentiation, and apoptosis.<sup>18,19</sup>

## 3 | VITAMIN D IMMUNOMODULATORY AND ANTIVIRAL ACTIVITY

In vitro studies show that vitamin D has immunomodulatory functions inhibiting cell proliferation, inducing cell differentiation and apoptosis in normal human cell types (normal human bronchial epithelial cells, monocyte-derived macrophages), and decreasing proinflammatory cytokine production. In addition vitamin D increases antiviral protein production, suggesting an important role in antiviral protection. These functions will be discussed in turn below.

### 3.1 | Vitamin D decreases proinflammatory cytokines in the lung

1 $\alpha$ ,25-Dihydroxyvitamin D directly modulates those cytokines that are dependent on nuclear factor  $\kappa$ B (NF- $\kappa$ B) activity, in many cells including macrophages, by blocking NF- $\kappa$ B p65 activation via upregulation of the NF- $\kappa$ B inhibitory protein I $\kappa$ B $\alpha$ .<sup>20</sup> Toll-like receptors (TLRs) are transmembrane proteins that recognize conserved molecular motifs of viral and bacterial origin and initiate innate immune responses. TLR3 recognizes viral double-stranded RNA or synthetic double-stranded RNA (polyinosinic-polycytidylic acid) and is primarily involved in defense against viruses. Vitamin D treatment has been shown to attenuate double-stranded RNA-TLR3-induced expression of IL-8 in respiratory epithelial cells.<sup>12</sup>

25-hydroxyvitamin D and 1,25(OH)<sub>2</sub>D also modulate T-cell adaptive immunity, decreasing the proinflammatory type 1 cytokines (IL-12, IFN- $\gamma$ , IL-6, IL-8 and tumor necrosis factor- $\alpha$ ) and IL-17 and increasing anti-inflammatory type 2 cytokines (IL-4, IL-5, and IL-10)<sup>21,22</sup> and regulatory T cells,<sup>23</sup> suggesting that a balance needs to be maintained to achieve a beneficial effect.

When primary CD4<sup>+</sup> T cells from normal donors were cultured in Th17-polarizing conditions, vitamin D reduced the expression of pathogenic Th17 markers and their secretion of proinflammatory cytokines (IL-17A and IFN- $\gamma$ ) and induced an expansion of CD25hi cells and upregulated their expression of CTLA-4 and Foxp3 regulatory markers.<sup>24</sup> Interestingly, the presence of the active form of vitamin D<sub>3</sub> during CD8<sup>+</sup> T-cell differentiation prevented IL-4-induced conversion to Tc2 IL-13 producers.<sup>25</sup>

In patients receiving oral vitamin D<sub>3</sub> (140 000 IU monthly) for 3 months, Tregs increased significantly.<sup>26</sup> Increased production of the suppressor cytokine IL-10 by non-CD4<sup>+</sup> non-CD8<sup>+</sup> T cells and decreased frequency of Th17 were reported in 4 healthy humans supplemented

with vitamin D<sub>3</sub> at a high dose (5000 to 10 000 IU/d).<sup>27</sup> In a randomized controlled trial in vitamin D-deficient patients, high-dose (4000 IU/d) vitamin D<sub>3</sub> for 2 months significantly reduced CD4<sup>+</sup> T cell-nonspecific activation as compared with the low dose (400 IU/d).<sup>28</sup>

### 3.2 | Antiviral activity

The local synthesis of vitamin D from its precursor 25(OH)D plays a crucial role in adequate local immune responses to respiratory virus infections.<sup>29</sup>

Human airway epithelial cells constitutively express VDR, high levels of activating 1 $\alpha$ (OH)ase, and low levels of inactivating 24(OH)ase.<sup>12,30</sup> Vitamin D generated by lung epithelium could lead to increased expression of antimicrobial peptides (such as cathelicidin [LL-37] and defensin  $\beta$ 4 [DEFB4, HBD2] in adjacent macrophages and other innate immune cells) (Figure 1).<sup>6,12,31</sup> In peripheral blood-derived cells, the highest levels of cathelicidin following treatment with 1,25(OH)<sub>2</sub>D were in macrophages, while lower levels were found in granulocyte-macrophage colony-stimulating factor-derived dendritic cells.<sup>32</sup>

There are data available supporting the antiviral activity of cathelicidin in infections with influenza A virus and respiratory syncytial virus (RSV)<sup>12,33–35</sup> by binding to virus, which leads to disruption of the virus envelope and modulation of cytokine and TLR3 responses.<sup>33</sup> Although defensin was induced by rhinovirus in primary epithelial cells, defensin showed no direct antiviral activity towards rhinovirus.<sup>36</sup> However, defensin inhibited RSV by destabilizing the viral envelope and consequently inhibiting cellular entry.<sup>37</sup>

Although to date there are no reports that vitamin D directly affects respiratory virus load, there are in vitro studies suggesting that vitamin D could contribute to reduced inflammation and less severe disease in RSV and influenza viral infections. In one study using epithelial cells isolated from tracheobronchial mucosa by enzymatic dissociation, 1,25(OH)<sub>2</sub>D treatment induced the NF- $\kappa$ B inhibitor I $\kappa$ B $\alpha$  and, consequently, RSV induction of NF- $\kappa$ B-driven genes—such as the antiviral IFN- $\beta$  and CXCL10—as well as antiviral IFN-stimulated genes (ISG) (myxovirus resistance A and ISG15) was downregulated.<sup>38</sup> However, the viral RNA or protein levels and viral replication were not increased.<sup>38</sup> Similarly, in vitro treatment of the human alveolar epithelial cell line A549 with 1,25(OH)<sub>2</sub>D (100/30 nM) prior to/after influenza A (H1N1) exposure decreased the levels of H1N1-induced proinflammatory cytokines and VDR in both experimental conditions,

restored the increased apoptosis seen on H1N1 infection back to the constitutive level, but did not affect viral clearance.<sup>39</sup> Interestingly, antiviral IFN- $\beta$  and ISG15 were decreased by 1,25(OH)<sub>2</sub>D treatment prior to influenza A exposure but were increased by 1,25(OH)<sub>2</sub>D treatment after exposure,<sup>39</sup> suggesting efficacy of 1,25(OH)<sub>2</sub>D treatment during a viral infection. However, the antiviral role of vitamin D was questioned in another in vitro study, showing that vitamin D does not have a direct effect on the replication of rhinovirus.<sup>40</sup>

Overall, in vitro studies suggest that vitamin D plays a significant role in local “respiratory homeostasis” either by directly affecting the replication of respiratory viruses or by inducing the expression of antimicrobial peptides, by modulating the balance of Th1/Th2 or Tc1/Tc2 responses, and by inhibiting Th17 cytokine production.<sup>25,41</sup>


## 4 | VITAMIN D DEFICIENCY AND RESPIRATORY VIRAL INFECTIONS IN HEALTHY AND ASTHMATIC PEOPLE

Influenza A and B, parainfluenza 1 and 2, and RSV infections are all more common in the winter, and, as all are enveloped viruses, all of them may be sensitive to antimicrobial peptides, and therefore vitamin D may be important in host defense against them. Epidemiological data have linked vitamin D deficiency to increased susceptibility to acute viral respiratory infections.<sup>42</sup> Some of these studies suggested that the enhanced vitamin D status during summer may be linked to the reduced prevalence of viral infections as compared with the winter months when lower plasma levels of vitamin D have been reported.<sup>43</sup> A proposed mechanism has been that UV-B radiation could trigger the production of the active form of vitamin D, 1,25(OH)<sub>2</sub>D, leading to increased production of antiviral peptides such as cathelicidin and defensins.

## 5 | VITAMIN D DEFICIENCY AND RESPIRATORY VIRAL INFECTIONS IN HEALTHY PERSONS

### 5.1 | Vitamin D deficiency and respiratory infections in newborns and children

There was an inverse association between cord blood 25(OH)D levels and risk of respiratory infection and childhood wheezing<sup>44</sup>; healthy



**FIGURE 1** The antiviral pathway of vitamin D, 1 $\alpha$ ,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) synthesized from 25-hydroxyvitamin D (25(OH)D), will act on vitamin D receptor (VDR) and induce the release of antiviral proteins (cathelicidin, defensins, and innate interferons) in the context of a respiratory viral infection

newborns with 25(OH)D <20 ng/mL in cord blood were 6 times more likely to develop RSV respiratory infection in the first year of life as compared with those with >30 ng/mL 25(OH)D.<sup>45</sup> Higher maternal circulating 25(OH)D concentrations in pregnancy were independently associated with reduced risk of lower respiratory tract infections (LRTIs) in offspring in the first year of life but not with wheezing or asthma in childhood,<sup>46</sup> and higher maternal midpregnancy 25(OH)D levels were associated with a modestly reduced risk of recurrent LRTI<sup>47</sup> by 36 months.

Serum 25(OH)D levels were associated with viral respiratory tract infection (RTI) in 743 children (3–15 y old)<sup>48</sup> followed between December 2008 and June 2009. A third of participants developed at least 1 viral RTI (confirmed by polymerase chain reaction in nasopharyngeal specimens). Serum 25(OH)D levels<sup>48</sup> under 75 nmol/L augmented the risk of viral RTIs by 50%, and levels <50 nmol/L by 70%.

## 5.2 | Vitamin D deficiency and respiratory infections in healthy adults

Data from a prospective cohort study over the autumn and winter of 2009–2010 in 198 healthy adults linked the levels of 25(OH)D to the recovery time from acute RTI (infection confirmed in nasopharyngeal swabs), suggesting that concentrations of  $\geq 38$  ng/mL of 25(OH)D may be associated with a markedly quicker recovery.<sup>49</sup>

In healthy adults 45 to 47 years of age, participants in the 1958 British nationwide birth cohort, the prevalence of respiratory infections had a strong seasonal pattern, opposing the direction of the 25(OH)D concentration pattern. Vitamin D status had a linear relationship with respiratory infections: each 10 nmol/L increase in 25(OH)D was associated with a 7% lower risk of self-reported acute respiratory infection (ARI).<sup>50</sup> These associations were confirmed in another large, nationally representative sample in the United States.<sup>42</sup> After season was adjusted for, demographic factors, and clinical data, in 14 108 participants in National Health and Nutrition Examination Survey 2001–2006, 25(OH)D levels <30 ng/mL were associated with 58% higher odds of ARI compared with  $\geq 30$  ng/mL levels.<sup>42</sup>

In another report, athletes with high vitamin D levels, 25(OH)D > 120 nmol/L, had fewer upper RTIs (URTI), less total number of URTI symptom days, and lower median symptom severity scores during a 4-month winter period than a vitamin D-deficient group with <30 nmol/L 25(OH)D.<sup>51</sup> The plasma cathelicidin concentration positively correlated with the plasma 25(OH)D concentration.

## 6 | VITAMIN D DEFICIENCY AND VIRAL-INDUCED EXACERBATIONS OF ASTHMA

Viral infections, mostly due to rhinoviruses, constitute the major cause of exacerbations of asthma.<sup>52</sup>

### 6.1 | Mothers and babies

A protective role of high maternal serum levels of vitamin D against viral infection was supported by several human and animal studies,<sup>53–56</sup> suggesting that high serum levels of vitamin D in pregnancy might protect the infant from developing ARIs or viral-induced

wheezing episodes within the first years of life. However, other studies were unable to support these associations<sup>57</sup> or highlight any protective effect of high maternal 25(OH)D concentrations on outcomes of allergic airway disease and lung function at early adulthood.<sup>58</sup>

### 6.2 | Asthmatic children

Several studies, principally in children, suggest that vitamin D insufficiency is associated with both asthma severity and poorer control.<sup>59–61</sup> Asthmatic children with low vitamin D levels suffer more severe exacerbations of the disease and have an increased risk of emergency department visits or hospitalizations.<sup>59,60,62</sup> There is also evidence linking vitamin D insufficiency and deficiency to an increased incidence of acute bronchiolitis. A recent systematic review and meta-analysis concluded that polymorphisms at the VDR level—which might be linked to functional vitamin D deficiency—are usually present in patients hospitalized because of severe RSV bronchiolitis, which is strongly associated with the development of wheezing and asthma later on in life.<sup>63</sup>

### 6.3 | Adult asthmatics

Ginde et al reported that the association between low 25(OH)D level and the incidence of URTI was stronger in individuals with asthma and chronic obstructive pulmonary disease: people with deficient circulating 25(OH)D (<25 nmol/L or <10 ng/mL) always exhibited a higher risk than people with adequate circulating 25(OH)D (>75 nmol/L or >30 ng/mL).<sup>64</sup>

In adult asthma, 25(OH)D levels below 30 ng/mL are common especially in patients with severe and/or uncontrolled asthma, in particular in patients with a sputum eosinophil count  $\geq 3\%$  despite treatment with inhaled and oral corticosteroids,<sup>65,66</sup> and levels correlate significantly with impaired lung function and poor response to treatment.<sup>65</sup>

In patients with mild to severe persistent asthma, vitamin D sufficiency was significantly associated with a decreased total number of asthma exacerbations, decreased total severe asthma exacerbations, and decreased emergency room visits, suggesting that vitamin D deficiency may be linked to the risk of severe asthma exacerbations in adults.<sup>67,68</sup>

Finally, elderly asthmatics commonly exhibit a profound vitamin D deficiency or insufficiency (also mirrored in their bone health status) and have poor control of the disease.<sup>69</sup> In a recent study in the United States, the group of older adults with asthma who presented with vitamin D deficiency had an increased number of hospitalizations and increased morbidity.<sup>70</sup> However, old people also probably spent less time outside and consequently were less exposed to UV-B radiation.

## 7 | SUMMARY

The majority of published evidence suggests that vitamin D deficiency is associated with negative outcomes in respiratory disease. This implies that supplementation with vitamin D might have a beneficial role on both the course and the outcome of these diseases and might provide significant benefit in terms of the quality of life of these patients. From a

recently published systematic review of randomized controlled trials, it can be concluded that, in the majority of people, daily intake of 1000 IU should result in >50 nmol/L circulating 25(OH)D levels<sup>71</sup> and that it is reasonable and safe to take approximately 1000 IU of vitamin D daily to optimize nonspecific immunity and prevent infection.<sup>72</sup>

## 8 | FORMS OF VITAMIN D SUPPLEMENTATION

The most common forms of inactive vitamin D used for supplementation are cholecalciferol/vitamin D<sub>3</sub> and ergocalciferol/vitamin D<sub>2</sub>. Given its longer serum half-life, greater potency, and lower cost, in theory, cholecalciferol/vitamin D<sub>3</sub> should be the preferred treatment for the correction of vitamin D deficiency.<sup>73,74</sup> Vitamin D<sub>3</sub> has been shown to be 87% more potent in raising and maintaining serum 25(OH)D concentrations and to produce up to 3-fold greater storage of vitamin D as compared with vitamin D<sub>2</sub> in equimolar amounts.<sup>73,75</sup>

Whether cholecalciferol/vitamin D<sub>3</sub> or ergocalciferol/vitamin D<sub>2</sub> is equally effective in increasing and maintaining serum 25(OH)D concentration is controversial.<sup>10</sup> Studies favoring ergocalciferol reported that the ingestion of 1000 IU ergocalciferol in vitamin D-insufficient adults is effective in raising total serum concentrations of 25(OH)D and in sustaining serum concentrations of total 1,25(OH)<sub>2</sub>D.<sup>76</sup> By contrast, in another study, in only 7 healthy participants, circulating 25(OH)D was increased from 27 to 43 ng/mL with a single oral dose of ergocalciferol (100 000 IU).<sup>77</sup>

The indications for vitamin D supplementation should be based on scientific evidence. It has been shown that only 25(OH)D levels <32 ng/mL positively correlate with both baseline antimicrobial cathelicidin levels and changes in cathelicidin levels following high-dose ergocalciferol treatment (50 000 IU every other day for 5 d) in healthy patients.<sup>78</sup> This implies that there is evidence that vitamin D supplementation could be recommended to prevent viral infections, but the baseline serum 25(OH)D levels will be a significant indication as to whether the supplementation will be effective. The treatment of persons with high 25(OH)D levels is not beneficial and is even dangerous. The supplementation trials should include only people with low baseline levels of 25(OH)D.<sup>5,7,79–81</sup>

In addition, intermittent high-dose vitamin D supplementation seems not to work as well as daily supplementation.<sup>82–85</sup> Bergman reported in a systematic review and a meta-analysis of published randomized controlled trials that vitamin D has a protective effect against RTIs; specifically, when using daily doses instead of intermittent large bolus doses at long intervals (1–3 mo) of vitamin D, a significantly better therapeutic effect is achieved.<sup>82,86</sup> When bolus vitamin D<sub>3</sub> (250 000 IU) was given once in November to young healthy adults, there was a robust increase in plasma 25(OH)D after 5 days, but after 90 days this effect was lost.<sup>87</sup> Intermittent dosing with vitamin D seems also to be less effective in reducing the incidence of exacerbations of asthma despite its favorable role in preventing bone fractures. However, an intermittent dosing scheme might improve adherence and could be directly observed.

The appropriate form of vitamin D supplementation might vary between the different respiratory conditions, and indeed between

supplementation for respiratory and bone disease and an evidence-based consensus on both the dose and the frequency needs to be reached.

## 9 | VITAMIN D SUPPLEMENTATION IN PREVENTING ARIs IN HEALTHY PEOPLE

The results from clinical trials of vitamin D supplementation in preventing and/or treating common colds in healthy subjects are inconsistent (Table 1). Values established as normal, insufficient, and deficient for circulating 25(OH)D were chosen to optimize bone health, and optimal levels of vitamin D for immune function were not considered in these studies. The majority of the studies show that maintaining serum 25(OH)D levels above 30 ng/mL (30 µg/L or 75 nmol/L) is associated with better respiratory outcomes. In some clinical trials vitamin D supplementation was not given to subjects with baseline serum 25(OH)D deficiency, and in other studies, the baseline levels of 25(OH)D were not measured. In addition, in some clinical trials the dose of vitamin D given was very low. Conversely, in some studies, intermittent, high-dose vitamin D was given, which may be suboptimal in time and is also possibly potentially dangerous immediately after administration: a high dose of vitamin D could be immunosuppressive.<sup>28,88</sup>

### 9.1 | Vitamin D<sub>3</sub> supplementation during pregnancy and infancy

Camargo et al reported that cord blood levels of 25(OH)D >75 nmol/L have inverse associations with risk of respiratory infection and childhood wheezing.<sup>44</sup>

Vitamin D<sub>3</sub> supplementation during pregnancy and infancy reduces primary care visits for ARIs during early childhood.<sup>89</sup> In a randomized, double-blind, placebo-controlled trial conducted in New Zealand, healthy pregnant women, from 27 weeks' gestation to birth, and their infants, from birth to age 6 months, were assigned to placebo or 1 of 2 doses of daily oral vitamin D<sub>3</sub> (1000 IU/400 IU or 2000 IU/800 IU).<sup>89</sup> The primary care records of enrolled children were inspected to age 18 months. In comparison with the placebo group, the proportion of children making any ARI visits was significantly smaller in the higher dose, but not the lower-dose vitamin D<sub>3</sub> group. The median number of visits per child for ARI was less in the higher-dose vitamin D<sub>3</sub> group from age 6 to 18 months (placebo 4, lower dose 3, higher dose 2.5; *P* = .048 for higher-dose vitamin D<sub>3</sub> versus placebo).<sup>89</sup>

A recent systematic review of correlation between in utero vitamin D exposure and childhood infection found that higher in utero vitamin D exposure lowers the risk of LRTI (pneumonia, bronchiolitis, croup, bronchitis, and/or otherwise unspecified chest infections) in young children.<sup>90</sup>

### 9.2 | Vitamin D<sub>3</sub> supplementation in preventing respiratory viral infections in healthy children

There are 2 studies in healthy children where preventive administration of vitamin D lowered the risk of respiratory infection.<sup>91,92</sup>

**TABLE 1** Selective clinical trials investigating the protective role of vitamin D during an acute respiratory infection in healthy individuals

| Interventional Clinical Trial Number                             | Type of Study                                                                    | Participants                                                                                                                                              | Description of the Study: Dose (IU) and Trial Duration                                                                                                                                                         | Posted/Published Results                                                                                                                                                                                                                                                                                      | Comments/Limits                                                                                                                                                                                                                                                                                                                                                                                                     |
|------------------------------------------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| UMIN000001373, PMID: 20219962, Urashima et al <sup>91</sup>      | randomized placebo-controlled double-blinded multicenter study                   | schoolchildren aged 6-15 vitamin D <sub>3</sub> (n = 167) or placebo (n = 167)                                                                            | 1200 IU/d vitamin D <sub>3</sub> or placebo for 4 winter months—incidence of influenza A and B and flu-like illness determined by antigen detection in nasopharyngeal swabs                                    | 42% lower risk of laboratory-confirmed influenza A infection in children in the vitamin D <sub>3</sub> group                                                                                                                                                                                                  | Positive study: low doses of vitamin D; baseline 25(OH)D levels not available                                                                                                                                                                                                                                                                                                                                       |
| NCT0086379, PMID: 22908115, Camargo et al <sup>92</sup>          | randomized placebo-controlled double-blinded multicenter study                   | Mongolian schoolchildren daily ingestion of milk fortified with 300 IU of vitamin D <sub>3</sub> (n = 143) or unfortified regular milk (control; n = 104) | milk fortified with 300 IU/d vitamin D <sub>3</sub> for 7 wk versus placebo; baseline serum 25(OH)D in intervention was 17.5 nmol/L and placebo 17.0 nmol/L                                                    | higher 25(OH)D levels at the end of the study (17.5 vs 47.3 nmol/L) in the fortified milk treated; 50% risk reduction in parent-reported ARI among children, ages 9-11; the decrease in ARI was seen in children both above and below the median baseline 25(OH)D levels                                      | Positive study: post hoc analysis; very low dose of vitamin D; short time; study started late in winter (January-March)                                                                                                                                                                                                                                                                                             |
| NCT00656929, PMID: 19296870, Li-Ng et al <sup>96</sup>           | randomized placebo-controlled double-blinded single-center study                 | adults (age 18-80) receiving vitamin D <sub>3</sub> (n = 78) versus placebo (n = 70)                                                                      | vitamin D <sub>3</sub> 2000 IU/d or placebo for 12 wk; biweekly questionnaire to record the incidence and severity of RTI symptoms over a 3-month period; baseline serum 25(OH)D measurement                   | 25(OH)D levels increased significantly from 64.3 to 88.5 nmol/L in the vitamin D group, not in placebo group, $P < .0001$ ; vitamin D <sub>3</sub> did not decrease the incidence or severity of symptomatic RTIs                                                                                             | Negative study: single-center self-reported RTIs; short time of administration (12 wk); high levels at baseline of 25(OH)D and no difference between groups; study over spring period only, April-June                                                                                                                                                                                                              |
| NCT01131858, PMID: 23242238, Bergman et al <sup>99</sup>         | randomized, placebo-controlled, double-blinded, single-center study              | patients with immunodeficiency with increased susceptibility to RTIs (>4 bacterial RTIs/year)                                                             | 4000 IU/d vitamin D <sub>3</sub> for 1 y versus placebo; baseline serum 25(OH)D in intervention was 51.5 nmol/L (n = 62) and placebo 46.9 nmol/L (n = 62)                                                      | 25(OH)D levels increased from 51.5 to 133.4 nmol/L after 3 mo and remain increased, $P < .001$ ; vitamin D <sub>3</sub> reduced the symptoms and antibiotic utilization among patients with immunodeficiency or frequent RTI, decreased number of days on antibiotics, increased vitamin D levels, $P < .001$ | Positive study: patient-reported information; single center, small sample size; a selected group of patients; not only healthy persons, the patient population was very heterogeneous with regard to immune deficiency and concomitant diseases (only few participants healthy, mostly ill with asthma; bronchiectasis; chronic obstructive pulmonary disease etc); incidence of viral infections was not addressed |
| NCT01182870, PMID: 22026455, Jorde et al <sup>98</sup>           | randomized, placebo-controlled, double-blinded, multicenter interventional study | adults received vitamin D (n = 289) versus placebo (n = 280)                                                                                              | different doses of vitamin D: 2000 IU/d; 2800 IU/d; 20 000 or 40 000 IU/wk; 100 000 IU vitamin D <sub>3</sub> , taken at 0, 2, and 4 mo; 100 000 IU taken every 4 wk during 1 y (n = 289) or placebo (n = 280) | supplementation with vitamin D in subjects randomized to vitamin D did not protect against "influenza"                                                                                                                                                                                                        | Negative study: post hoc analysis; retrospective study that relied on self-reported symptoms; baseline 25(OH)D levels not available; some patients with very high bolus dose of vitamin D                                                                                                                                                                                                                           |
| ACTRN12609000486224, PMID: 23032549, Murdoch et al <sup>83</sup> | randomized, placebo-controlled, double-blinded, multicenter study                | adults with near-normal vitamin D levels (over 29 ng/mL) received vitamin D (n = 161)                                                                     | participants received an initial dose of 200 000 IU oral vitamin D <sub>3</sub> , then 200 000 IU 1 mo later, then 100 000 IU/mo for a total of 18 mo;                                                         | 25(OH)D levels increased from 72.5 to 122.5 nmol/L, $P < .001$ ; no significant difference in                                                                                                                                                                                                                 | Negative study: levels at baseline of 25(OH)D, nearly sufficient in both treated and control groups; high bolus doses administered                                                                                                                                                                                                                                                                                  |

(Continues)

|                                                                 |                                                      |                                                                                                                                          |                          |                                                                                                                                                                                                            |                                                                                                                                                                      |                                                                                                                                                                                                                                         |
|-----------------------------------------------------------------|------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NCT01158560,<br>PMID: 24885201,<br>Goodall et al <sup>100</sup> | randomized, placebo-controlled trial                 | students 17 y of age or older received vitamin D (n = 70) versus placebo (n = 80)                                                        | versus placebo (n = 161) | baseline serum 25(OH)D in intervention was 72.5 nmol/L and placebo 70.0 nmol/L; questionnaire to record the number, duration, severity of RTIs; PCR of nasopharyngeal swabs for viruses                    | reported or laboratory-confirmed number of upper RTIs                                                                                                                | Positive study: short time of administration; 10% of subject with asthma<br><br>supplementation with vitamin D was associated with 46% risk reduction of laboratory-confirmed viral RTIs and may reduce the risk of clinical infections |
| NCT01069874<br>PMID: 26063508<br>Martineau et al <sup>84</sup>  | randomized, placebo-controlled, double-blinded study | active treatments: 137; participants: 115 sheltered accommodation and 22 carers, versus control participants: 79 sheltered and 24 carers |                          | residents: daily dose of 400 IU + 6 times (X) bolus of 96 000 IU every 2 mo vitamin D <sub>3</sub> ; carers: 6 X bolus of 120 000 IU every 2 mo vitamin D <sub>3</sub> versus placebo over a period of 1 y | 25(OH)D levels increased, 42.4 to 85.3 nmol/L; supplementation with vitamin D was not associated with a decrease in RTI, but with increased risk and duration of URI | Negative study: mixture of sheltered accommodation residents and carers subjects; mixed ethnicity; high bolus doses of vitamin D <sub>3</sub>                                                                                           |

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ARI, acute respiratory infection; PCR, polymerase chain reaction; PMID, PubMed identifier; RTI, respiratory tract infection.

Influenza A occurred in 10.8% of a group of 167 schoolchildren receiving 1200 IU/d vitamin D<sub>3</sub>. This was significantly lower than the placebo group where over 18.6% of children were infected.<sup>91</sup>

In a recent systematic review of vitamin D supplementation to prevent ARI (influenza and pneumonia) in healthy kids, Xiao et al<sup>93</sup> found that from 4 clinical trials<sup>91,92,94,95</sup> only in Urashima's study, where the risk of viral infection was lowered, was the vitamin D supplementation<sup>91</sup> 1200 IU/d. In 2 studies, where vitamin D supplementation was at a low dose or administered as a 3-monthly bolus of 100 000 IU, the ARIs were not reduced in healthy children.<sup>94,95</sup>

### 9.3 | Vitamin D<sub>3</sub> supplementation in preventing respiratory viral infections in healthy adults

In contrast, the majority of vitamin D supplementation studies in adults reported negative results.

Vitamin D supplementation had no effect in healthy persons with self-reported upper respiratory infection (URI).<sup>83,96</sup> In a 3-month prospective placebo-controlled trial of vitamin D<sub>3</sub> supplementation, a dose of 2000 IU/d of cholecalciferol in ambulatory adults decreased neither the incidence nor the severity of symptomatic URTI during winter.<sup>96,97</sup> A lack of effect was also seen in a study in New Zealand with over 29 ng/mL mean baseline 25(OH)D level of participants.<sup>83</sup> Vitamin D supplementation (vitamin D<sub>3</sub>, 200000 IU, then 200000 IU 1 mo later, then 100 000 IU monthly thereafter for a total of 18 mo) resulted in an increase in serum 25(OH)D levels that were maintained at greater than 48 ng/mL throughout the study, but there was no difference in the incidence of URTI of sufficient severity to bring them to medical attention. However, both vitamin D-treated and placebo groups had serum levels of 25(OH)D above deficiency and similar at baseline: 64.3 nmol/L in the vitamin D group versus 63.0 nmol/L in the placebo group<sup>96</sup> and 72 nmol/L in the vitamin D group versus 70 nmol/L in the placebo group.<sup>83</sup>

In another report, in 569 subjects from 10 different placebo-controlled clinical trials of vitamin D supplementation, of whom 289 received vitamin D (1111-6800 IU/d) and 280 received placebo,<sup>98</sup> influenza-like disease did not differ, although the duration of illness was significantly longer among those in the vitamin D group. The results do not support the hypothesis that high doses of vitamin D supplementation will have a pronounced effect on influenza-like disease in populations not having a high influenza risk.<sup>98</sup>

Bergman, in a study in adult patients with antibody deficiency or frequent RTI, reported that 4000 IU/d cholecalciferol reduced symptoms and antibiotic utilization.<sup>99</sup>

In university students who completed weekly electronic surveys and submitted self-collected midturbinate nasal swabs, vitamin D<sub>3</sub> supplementation at doses of 10 000 IU/wk significantly reduced the risk of URTI, with a significantly lower mean viral load.<sup>100</sup> Clinical URTI were reported in 23.3% of a group of 70 participants receiving vitamin D<sub>3</sub> as compared with 26.7% of 80 participants receiving placebo.

In a clinical trial of intermittent high-dose vitamin D<sub>3</sub> versus low-dose vitamin D<sub>3</sub> supplementation for ARI prevention in residents of sheltered-accommodation housing blocks and their carers in London, United Kingdom, the addition of intermittent bolus dose vitamin D<sub>3</sub> supplementation to a daily low-dose regimen did not influence risk of

ARI in older adults and their carers but on the contrary was associated with increased risk and duration of URIs.<sup>84</sup> Inadequate vitamin D status was common at baseline: 220 of 240 (92%) participants had serum 25(OH)D concentration <75 nmol/L. The active intervention did not influence time to first ARI. In fact, when URI and lower respiratory infections were analyzed separately, allocation to the active intervention was associated with increased risk of URI and increased duration of URI symptoms, but not with altered risk or duration of lower respiratory infection.

Simpson et al reported that a protective vitamin D effect (20 000 IU/wk cholecalciferol 17 wk during winter) towards acute infections (respiratory, gastrointestinal, urinary tract, eye, ear, skin, and cold sore infections) could only be observed in the subgroup of healthy adults with initial 25(OH)D levels <40 nmol/L ( $n = 4$  of 34 healthy adults).<sup>101</sup> No microbiological verification of symptoms was available.

## 10 | VITAMIN D SUPPLEMENTATION IN PREVENTING RESPIRATORY INFECTION IN PATIENTS WITH ASTHMA

Although epidemiological studies have revealed a strong association between lower vitamin D levels and increased asthma exacerbations, suggesting that these patients would benefit from vitamin D supplementation, there are few studies that show efficacy of vitamin D supplementation. Several studies used a high dose of vitamin D and intermittent administration as bolus dose, whose efficacy is questioned.<sup>102–104</sup>

A cause of inefficacy of vitamin D in preventing viral infection in allergic asthma could be the characteristic high levels of type 2 cytokine IL-4 and IL-13, which could initiate the catabolism of vitamin D, affect VDR levels, induce type 1 to type 2 conversion of T cells.<sup>25,105–108</sup>

### 10.1 | Vitamin D supplementation in pregnant women in preventing wheezing in offspring

Vitamin D supplementation of pregnant women did not protect the offspring from developing recurrent wheezing episodes or physician diagnosed asthma later in life.<sup>109,110</sup>

In a double-blind, placebo-controlled trial conducted in India, 230 mother-newborn pairs were randomized to receive, monthly for 9 months, a high dose of cholecalciferol (3000 µg = 120 000 IU) for the mother (group A) or 10 µg = 400 IU/d for the infant (group B) or double placebo (group C).<sup>104</sup> At 3.5 months, infants' median 25(OH)D was lower in placebo group C (45.3 nmol/L) than in group A (60.8 nmol/L) or B (61.3 nmol/L). There were no significant differences between groups in respiratory infections (we do not know how respiratory infections were diagnosed) over 9 months. There are no results concerning the differences between baseline and 3.5 months.

In 2 recent well-designed clinical trials, vitamin D supplementation did not decrease significantly the incidence of RTIs.<sup>111,112</sup> In a multiracial cohort of pregnant women at high risk of having a child with asthma, the supplementation with vitamin D at doses of 4400 IU/d, although significantly increased vitamin D levels, did not significantly

decrease the incidence of LRTI and recurrent wheezing in their children at age 3 years as compared with a group taking only 400 IU/d vitamin D.<sup>111</sup> However, the authors recognized that the studies may have been underpowered and short in time. The high risk of having a child with asthma means that the group was not homogenous: the mother or the father has a range of very different diseases such as asthma (not specified if allergic or nonallergic), eczema, and allergic rhinitis. Other causes for a negative study results could be that the group was multiracial and the dose of vitamin D was too small.

Another study found that supplementation with 2800 vs 400 IU/d of vitamin D during the third trimester of pregnancy did not result in a statistically significant reduced risk of persistent wheezing in the offspring through 3 years of age.<sup>112</sup> Vitamin D supplementation did not influence the number of URTI (episodes of common cold, acute tonsillitis, croup, and acute otitis media) or LRTI (pneumonia and bronchiolitis). The authors admitted a reduced statistical power of the study and that the vitamin D supplementation doses may have been too low. In addition, the authors commented that they may have begun supplementation too late (only 81% of the women had serum vitamin D above 30 ng/mL after the intervention). Finally, the study did not include postnatal supplementation of the children, which could have induced an additive effect if the effects of maternal supplementation declined postnatally.

### 10.2 | Vitamin D supplementation in preventing asthma exacerbations in children

Episodes of airway obstruction with wheezing, which are mostly triggered by viral infection in the first 3 years of life, although transient, are a major cause of morbidity, and hospitalization rates are high.<sup>113,114</sup>

In 2 randomized, placebo-controlled double-blind multicenter studies in children, vitamin D supplementation reduced ARI and asthma attacks in children with vitamin D deficiency.<sup>91,93,94</sup> In school-aged children, vitamin D<sub>3</sub> supplementation at 1200 IU/d reduced the incidence of symptomatic influenza A infections during the influenza season and reduced the number of asthma attacks.<sup>91</sup>

### 10.3 | Vitamin D supplementation in preventing asthma exacerbations in adults

In a recent trial (Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma) that assessed the effect of vitamin D supplementation to adults with persistent asthma with vitamin D deficiency (serum 25(OH)D < 30 ng/mL), vitamin D<sub>3</sub> (100 000 IU once, then 4000 IU/d for 28 wk) did not reduce asthma exacerbations.<sup>102</sup> However, the trial was underpowered, and when analyses were limited to those that achieved a sufficient level of vitamin D (30 ng/mL or greater), an effect was seen for decreasing the overall number of asthma exacerbations.<sup>115</sup>

In another study, a bolus dose of vitamin D<sub>3</sub> supplementation did not influence time to exacerbation or URI in a population of adults with asthma with a high prevalence of baseline vitamin D insufficiency.<sup>103</sup>

A current ongoing study VITAL will evaluate the effect of vitamin D supplementation, 2000 IU, administered once per day, rather than intermittent large boluses, on acute exacerbations of asthma.<sup>115</sup>

## 11 | CONCLUSIONS

Vitamin D has been shown to increase the antiviral and anti-inflammatory responses of airway epithelial cells during respiratory viral infections in vitro. There is definite evidence for an association between vitamin D deficiency and an incidence of pulmonary exacerbations in chronic airway diseases such as asthma. However, the results from clinical trials of vitamin D supplementation in preventing or ameliorating treating RTIs are inconsistent. The negative results could be due to underpowered studies, a lower dose of vitamin D, a high dose of vitamin D given at a large interval of time, dosing schedule, short follow-up time, use of supplementation in subjects with normal 25(OH)D levels, self-reporting of the cold/infection, and, very frequent, the absence of a laboratory diagnostic of the viral infection.

Better-designed clinical studies, using (i) cholecalciferol/vitamin D<sub>3</sub>, (ii) given vitamin D in a daily rather than as intermittent high dose, (iii) for longer than 3 months, (iv) in placebo-controlled homogenous large groups with deficient 25(OH)D levels, could confirm its efficiency in preventing viral infection and virus-induced exacerbations of asthma. In addition, vitamin D could increase the efficacy of medications such as corticosteroids in preventing respiratory exacerbations of these diseases. More studies investigating the role of vitamin D deficiency in respiratory disease are eagerly anticipated.

## ACKNOWLEDGEMENTS

This work was funded by the Wellcome Trust (grants 063717 and 083567/Z/07/Z for the Centre for Respiratory Infection); the Romanian Ministry of National Education, CNCS—UEFISCDI project number PN-II-ID-PCE-2012-4-0417 (L.A.S., M.T.Z., and C.B.); the British Medical Association and Rosetrees Trust Grant (H.M.); the European Research Council (FP7 Advanced Grant 233015, S.L.J.); the Medical Research Council Centre (grant no. G1000758, S.L.J.). A.B. was supported by the NIHR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.

The sponsors had no involvement in the study design, analysis and interpretation of data, the manuscript preparation and revision and the decision to submit the manuscript for publication.

## CONFLICT OF INTEREST

S.L. Johnston has received consulting fees from GlaxoSmithKline, Chiesi, Boehringer Ingelheim, Novartis, Sanofi Pasteur, Centocor, Grünenthal, and Synairgen. S.L.J. is one of the authors on patents relating to the use of interferons in treatment of exacerbations of airway disease and holds share options in Synairgen, a company developing interferons for treatment of exacerbations of airway disease.

M.T. Zdrengha, Heidi Makrinioti, Cristina Bagacean, A. Bush, and Luminita A. Stanciu have nothing to disclose.

## REFERENCES

- Kain K. Some clinical trials are driven by fashion, not science. *BMJ*. 2015;350:h288. doi: 10.1136/bmj.h288
- Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. *BMJ*. 2014;348:g2035. doi: 10.1136/bmj.g2035
- Jolliffe DA, Griffiths CJ, Martineau AR. Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies. *J Steroid Biochem Mol Biol*. 2013;136:321–329. doi: 10.1016/j.jsbmb.2012.11.017
- Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence. *CMAJ*. 2014;186:190–199. doi: 10.1503/cmaj.121442
- Bryson KJ, Nash AA, Norval M. Does vitamin D protect against respiratory viral infections? *Epidemiol Infect*. 2014;142:1789–1801. doi: 10.1017/S0950268814000193
- Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science*. 2006;311:1770–1773.
- Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab*. 2011;96:53–58. doi: 10.1210/jc.2010-2704
- Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respond to Endocrine Society vitamin D guideline. *J Clin Endocrinol Metab*. 2012;97:1146–1152. doi: 10.1210/jc.2011-2218
- Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2011;96:1911–1930. doi: 10.1210/jc.2011-0385
- Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. *J Steroid Biochem Mol Biol*. 2014;144(Pt A):132–137. doi: 10.1016/j.jsbmb.2013.09.012
- Fritsche J, Mondal K, Ehrnsperger A, Andreesen R, Kreutz M. Regulation of 25-hydroxyvitamin D<sub>3</sub>-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D<sub>3</sub> by human dendritic cells. *Blood*. 2003;102:3314–3316. doi: 10.1182/blood-2002-11-3521
- Hansdottir S, Monick MM, Hinde SL, Lohan N, Look DC, Hunninghake GW. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. *J Immunol*. 2008;181:7090–7099. DOI: 181/10/7090 [pii]
- Adams JS, Liu PT, Chun R, Modlin RL, Hewison M. Vitamin D in defense of the human immune response. *Ann N Y Acad Sci*. 2007;1117:94–105.
- Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. *Trends Biochem Sci*. 2004;29:664–673.
- Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. *Am J Clin Nutr*. 1999;69:842–856.
- Wagner D, Dias AG, Schnabl K, Van der Kwast T, Vieth R. Determination of 1,25-dihydroxyvitamin D concentrations in human colon tissues and matched serum samples. *Anticancer Res*. 2012;32:259–263.
- Matilainen JM, Malinen M, Turunen MM, Carlberg C, Vaisanen S. The number of vitamin D receptor binding sites defines the different vitamin D responsiveness of the CYP24 gene in malignant and normal mammary cells. *J Biol Chem*. 2010;285:24174–24183. doi: 10.1074/jbc.M110.124073
- Haussler MR, Jurutka PW, Mizwicki M, Norman AW. Vitamin D receptor (VDR)-mediated actions of 1alpha,25(OH)<sub>2</sub>vitamin D<sub>3</sub>: genomic and non-genomic mechanisms. *Best Pract Res Clin Endocrinol Metab*. 2011;25:543–559. doi: 10.1016/j.beem.2011.05.010
- Campbell MJ. Vitamin D and the RNA transcriptome: more than mRNA regulation. *Front Physiol*. 2014;5:181. doi: 10.3389/fphys.2014.00181
- Chen Y, Zhang J, Ge X, Du J, Deb DK, Li YC. Vitamin D receptor inhibits nuclear factor kappa B activation by interacting with IkappaB

- kinase beta protein. *J Biol Chem*. 2013;288:19450–19458. doi: 10.1074/jbc.M113.467670
21. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D<sub>3</sub>: preferential inhibition of Th1 functions. *J Nutr*. 1995;125:1704S–1708S.
22. Zhang Y, Leung DY, Richers BN, et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. *J Immunol*. 2012;188:2127–2135. doi: 10.4049/jimmunol.1102412
23. Jeffery LE, Burke F, Mura M, et al. 1,25-Dihydroxyvitamin D<sub>3</sub> and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. *J Immunol*. 2009;183:5458–5467. doi: 10.4049/jimmunol.0803217
24. Fawaz L, Mrad MF, Kazan JM, Sayegh S, Akika R, Khoury SJ. Comparative effect of 25(OH)D<sub>3</sub> and 1,25(OH)<sub>2</sub>D<sub>3</sub> on Th17 cell differentiation. *Clin Immunol*. 2016;166–167:59–71. doi: 10.1016/j.clim.2016.02.011
25. Schedel M, Jia Y, Michel S, et al. 1,25D<sub>3</sub> prevents CD8(+)Tc2 skewing and asthma development through VDR binding changes to the Cyp11a1 promoter. *Nat Commun*. 2016;7:10213. doi: 10.1038/ncomms10213
26. Bock G, Prietl B, Mader JK, et al. The effect of vitamin D supplementation on peripheral regulatory T cells and beta cell function in healthy humans: a randomized controlled trial. *Diabetes Metab Res Rev*. 2011;27:942–945. doi: 10.1002/dmrr.1276
27. Allen AC, Kelly S, Basdeo SA, et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. *Mult Scler*. 2012;18:1797–1800. doi: 10.1177/1352458512442992
28. Konijeti GG, Arora P, Boylan MR, et al. Vitamin D supplementation modulates T cell-mediated immunity in humans: results from a randomized control trial. *J Clin Endocrinol Metab*. 2016;101:533–538. doi: 10.1210/jc.2015-3599
29. Hewison M. Vitamin D and immune function: autocrine, paracrine or endocrine? *Scand J Clin Lab Invest Suppl*. 2012;243:92–102. doi: 10.3109/00365513.2012.682862
30. Hansdottir S, Monick MM. Vitamin D effects on lung immunity and respiratory diseases. *Vitam Horm*. 2011;86:217–237. doi: 10.1016/B978-0-12-386960-9.00009-5
31. Kho AT, Sharma S, Qiu W, et al. Vitamin D related genes in lung development and asthma pathogenesis. *BMC Med Genomics*. 2013;6:47. doi: 10.1186/1755-8794-6-47
32. Lowry MB, Guo C, Borregaard N, Gombart AF. Regulation of the human cathelicidin antimicrobial peptide gene by 1alpha,25-dihydroxyvitamin D<sub>3</sub> in primary immune cells. *J Steroid Biochem Mol Biol*. 2014;143:183–191. doi: 10.1016/j.jsbmb.2014.02.004
33. Tripathi S, Tecle T, Verma A, Crouch E, White M, Hartshorn KL. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. *J Gen Virol*. 2013;94:40–49. doi: 10.1099/vir.0.045013-0
34. Currie SM, Findlay EG, McHugh BJ, et al. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. *PLoS One*. 2013;8:e73659. doi: 10.1371/journal.pone.0073659
35. Mansbach JM, Piedra PA, Borregaard N, et al. Serum cathelicidin level is associated with viral etiology and severity of bronchiolitis. *J Allergy Clin Immunol*. 2012;130:1007–1008 e1001. doi: 10.1016/j.jaci.2012.07.044
36. Proud D, Sanders SP, Wiehler S. Human rhinovirus infection induces airway epithelial cell production of human beta-defensin 2 both in vitro and in vivo. *J Immunol*. 2004;172:4637–4645.
37. Kota S, Sabbah A, Chang TH, et al. Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. *J Biol Chem*. 2008;283:22417–22429. doi: 10.1074/jbc.M710415200
38. Hansdottir S, Monick MM, Lovan N, Powers L, Gerke A, Hunninghake GW. Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. *J Immunol*. 2010;184:965–974. doi: 10.4049/jimmunol.0902840
39. Khare D, Godbole NM, Pawar SD, et al. Calcitriol [1, 25(OH)<sub>2</sub>D<sub>3</sub>] pre- and post-treatment suppresses inflammatory response to influenza A (H1N1) infection in human lung A549 epithelial cells. *Eur J Nutr*. 2013;52:1405–1415. doi: 10.1007/s00394-012-0449-7
40. Brockman-Schneider RA, Pickles RJ, Gern JE. Effects of vitamin D on airway epithelial cell morphology and rhinovirus replication. *PLoS One*. 2014;9:e86755. doi: 10.1371/journal.pone.0086755
41. Nanzer AM, Chambers ES, Ryanna K, et al. Enhanced production of IL-17A in patients with severe asthma is inhibited by 1alpha,25-dihydroxyvitamin D<sub>3</sub> in a glucocorticoid-independent fashion. *J Allergy Clin Immunol*. 2013;132:297–304 e293. doi: 10.1016/j.jaci.2013.03.037
42. Monlezun DJ, Bittner EA, Christopher KB, Camargo CA, Quraishi SA. Vitamin D status and acute respiratory infection: cross sectional results from the United States National Health and Nutrition Examination Survey, 2001–2006. *Nutrients*. 2015;7:1933–1944. doi: 10.3390/nu7031933
43. Walker VP, Modlin RL. The vitamin D connection to pediatric infections and immune function. *Pediatr Res*. 2009;65:106R–113R. doi: 10.1203/PDR.0b013e31819dba91
44. Camargo CA Jr, Ingham T, Wickens K, et al. Cord-blood 25-hydroxyvitamin D levels and risk of respiratory infection, wheezing, and asthma. *Pediatrics*. 2011;127:e180–e187. doi: 10.1542/peds.2010-0442
45. Belderbos ME, Houben ML, Wilbrink B, et al. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. *Pediatrics*. 2011;127:e1513–e1520. doi: 10.1542/peds.2010-3054
46. Morales E, Romieu I, Guerra S, et al. Maternal vitamin D status in pregnancy and risk of lower respiratory tract infections, wheezing, and asthma in offspring. *Epidemiology*. 2012;23:64–71. doi: 10.1097/EDE.0b013e31823a44d3
47. Magnus MC, Stene LC, Haberg SE, et al. Prospective study of maternal mid-pregnancy 25-hydroxyvitamin D level and early childhood respiratory disorders. *Paediatr Perinat Epidemiol*. 2013;27:532–541. doi: 10.1111/ppe.12080
48. Science M, Maguire JL, Russell ML, Smieja M, Walter SD, Loeb M. Low serum 25-hydroxyvitamin D level and risk of upper respiratory tract infection in children and adolescents. *Clin Infect Dis*. 2013;57:392–397. doi: 10.1093/cid/cit289
49. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. *PLoS One*. 2010;5:e11088. doi: 10.1371/journal.pone.0011088
50. Berry DJ, Hesketh K, Power C, Hypponen E. Vitamin D status has a linear association with seasonal infections and lung function in British adults. *Br J Nutr*. 2011;106:1433–1440. doi: 10.1017/S0007114511001991
51. He CS, Handzlik M, Fraser WD, et al. Influence of vitamin D status on respiratory infection incidence and immune function during 4 months of winter training in endurance sport athletes. *Exerc Immunol Rev*. 2013;19:86–101.
52. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. *BMJ*. 1995;310:1225–1229.
53. Chi A, Wildfire J, McLoughlin R, et al. Umbilical cord plasma 25-hydroxyvitamin D concentration and immune function at birth: the Urban Environment and Childhood Asthma study. *Clin Exp Allergy*. 2011;41:842–850. doi: 10.1111/j.1365-2222.2011.03712.x
54. Thorne-Lyman A, Fawzi WW. Vitamin D during pregnancy and maternal, neonatal and infant health outcomes: a systematic review and

- meta-analysis. *Paediatr Perinat Epidemiol.* 2012;26(Suppl 1):75–90. doi: 10.1111/j.1365-3016.2012.01283.x
55. Foong RE, Bosco A, Jones AC, et al. In utero vitamin D deficiency increases airway smooth muscle mass and impairs lung function. *Am J Respir Cell Mol Biol.* 2015. doi: 10.1165/rcmb.2014-0356OC
  56. Vasilou JE, Lui S, Walker SA, et al. Vitamin D deficiency induces Th2 skewing and eosinophilia in neonatal allergic airways disease. *Allergy.* 2014;69:1380–1389. doi: 10.1111/All.12465
  57. Pike KC, Inskip HM, Robinson S, et al. Maternal late-pregnancy serum 25-hydroxyvitamin D in relation to childhood wheeze and atopic outcomes. *Thorax.* 2012;67:950–956. doi: 10.1136/thoraxjnl-2012-201888
  58. Hansen S, Maslova E, Strom M, et al. The long-term programming effect of maternal 25-hydroxyvitamin D in pregnancy on allergic airway disease and lung function in offspring after 20 to 25 years of follow-up. *J Allergy Clin Immunol.* 2015. doi: 10.1016/j.jaci.2014.12.1924
  59. Brehm JM, Celedon JC, Soto-Quiros ME, et al. Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica. *Am J Respir Crit Care Med.* 2009;179:765–771. doi: 10.1164/rccm.200808-1361OC
  60. Brehm JM, Schuemann B, Fuhlbrigge AL, et al. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. *J Allergy Clin Immunol.* 2010;126:52–58 e55. doi: 10.1016/j.jaci.2010.03.043
  61. Gupta A, Sjoukes A, Richards D, et al. Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma. *Am J Respir Crit Care Med.* 2011;184:1342–1349. doi: 10.1164/rccm.201107-1239OC
  62. Brehm JM, Acosta-Perez E, Klei L, et al. Vitamin D insufficiency and severe asthma exacerbations in Puerto Rican children. *Am J Respir Crit Care Med.* 2012;186:140–146. doi: 10.1164/rccm.201203-0431OC
  63. McNally JD, Sampson M, Matheson LA, Hutton B, Little J. Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis. *Pediatr Pulmonol.* 2014;49:790–799. doi: 10.1002/Ppul.22877
  64. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med.* 2009;169:384–390. doi: 10.1001/archinternmed.2008.560
  65. Sutherland ER, Goleva E, Jackson LP, Stevens AD, Leung DY. Vitamin D levels, lung function, and steroid response in adult asthma. *Am J Respir Crit Care Med.* 2010;181:699–704. doi: 10.1164/rccm.200911-1710OC
  66. Korn S, Hubner M, Jung M, Blettner M, Buhl R. Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. *Respir Res.* 2013;14:25. doi: 10.1186/1465-9921-14-25
  67. Salas NM, Luo L, Harkins MS. Vitamin D deficiency and adult asthma exacerbations. *J Asthma.* 2014;51:950–955. doi: 10.3109/02770903.2014.930883
  68. Confino-Cohen R, Brufman I, Goldberg A, Feldman BS. Vitamin D, asthma prevalence and asthma exacerbations: a large adult population-based study. *Allergy.* 2014;69:1673–1680. doi: 10.1111/all.12508
  69. Columbo M, Panettieri RA Jr, Rohr AS. Asthma in the elderly: a study of the role of vitamin D. *Allergy Asthma Clin Immunol.* 2014;10:48. doi: 10.1186/1710-1492-10-48
  70. Tsai CL, Delclos GL, Huang JS, Hanania NA, Camargo CA Jr. Age-related differences in asthma outcomes in the United States, 1988–2006. *Ann Allergy Asthma Immunol.* 2013;110:240–246 e241. doi: 10.1016/j.anai.2013.01.002
  71. Zittermann A, Ernst JB, Gummert JF, Borgermann J. Vitamin D supplementation, body weight and human serum 25-hydroxyvitamin D response: a systematic review. *Eur J Nutr.* 2014;53. doi: 10.1007/s00394-013-0634-3
  72. Zittermann A, Pilz S, Hoffmann H, Marz W. Vitamin D and airway infections: a European perspective. *Eur J Med Res.* 2016;21:14. doi: 10.1186/s40001-016-0208-y
  73. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. *J Clin Endocrinol Metab.* 2011;96:E447–E452. doi: 10.1210/jc.2010-2230
  74. Bischoff-Ferrari HA, Dawson-Hughes B, Stocklin E, et al. Oral supplementation with 25(OH)D<sub>3</sub> versus vitamin D<sub>3</sub>: effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunity. *J Bone Miner Res.* 2012;27:160–169. doi: 10.1002/jbmr.551
  75. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D<sub>2</sub>) as a vitamin supplement. *Am J Clin Nutr.* 2006;84:694–697.
  76. Biancuzzo RM, Clarke N, Reitz RE, Trivison TG, Holick MF. Serum concentrations of 1,25-dihydroxyvitamin D<sub>2</sub> and 1,25-dihydroxyvitamin D<sub>3</sub> in response to vitamin D<sub>2</sub> and vitamin D<sub>3</sub> supplementation. *J Clin Endocrinol Metab.* 2013;98:973–979. doi: 10.1210/jc.2012-2114
  77. Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. *J Am Soc Nephrol.* 2014;25:564–572. doi: 10.1681/ASN.2013040355
  78. Bhan I, Camargo CA Jr, Wenger J, et al. Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. *J Allergy Clin Immunol.* 2011;127:1302–1304 e1301. doi: 10.1016/j.jaci.2010.12.1097
  79. Cannell JJ, Zasloff M, Garland CF, Scragg R, Giovannucci E. On the epidemiology of influenza. *Virol J.* 2008;5:29. doi: 10.1186/1743-422X-5-29
  80. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. *Ann Epidemiol* 2009;19:73–78. DOI: S1047-2797 (08)00002-1 [pii]. doi: 10.1016/j.annepidem.2007.12.001
  81. Lappe JM, Heaney RP. Why randomized controlled trials of calcium and vitamin D sometimes fail. *Dermatoendocrinol.* 2012;4:95–100. doi: 10.4161/derm.19833
  82. Hollis BW, Wagner CL. Clinical review: the role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. *J Clin Endocrinol Metab.* 2013;98:4619–4628. doi: 10.1210/jc.2013-2653
  83. Murdoch DR, Slow S, Chambers ST, et al. Effect of vitamin D<sub>3</sub> supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. *JAMA.* 2012;308:1333–1339. doi: 10.1001/jama.2012.12505
  84. Martineau AR, Hanifa Y, Witt KD, et al. Double-blind randomised controlled trial of vitamin D<sub>3</sub> supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). *Thorax.* 2015. doi: 10.1136/thoraxjnl-2015-206996
  85. Weiss ST, Litonjua AA. Vitamin D dosing for infectious and immune disorders. *Thorax.* 2015. doi: 10.1136/thoraxjnl-2015-207334
  86. Bergman P, Lindh AU, Bjorkhem-Bergman L, Lindh JD. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. *PLoS One.* 2013;8:e65835. doi: 10.1371/journal.pone.0065835
  87. Kearns MD, Binongo JN, Watson D, et al. The effect of a single, large bolus of vitamin D in healthy adults over the winter and following year: a randomized, double-blind, placebo-controlled trial. *Eur J Clin Nutr.* 2015;69:193–197. doi: 10.1038/ejcn.2014.209
  88. Kimball S, Vieth R, Dosch HM, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. *J Clin Endocrinol Metab.* 2011;96:2826–2834. doi: 10.1210/jc.2011-0325
  89. Grant CC, Kaur S, Waymouth E, et al. Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial. *Acta Paediatr.* 2015;104:396–404. doi: 10.1111/apa.12819
  90. Fried DA, Rhyu J, Odato K, Blunt H, Karagas MR, Gilbert-Diamond D. Maternal and cord blood vitamin D status and childhood infection and

- allergic disease: a systematic review. *Nutr Rev.* 2016;74:387–410. doi: 10.1093/nutrit/nuv108
91. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr.* 2010;91:1255–1260. doi: 10.3945/ajcn.2009.29094
  92. Camargo CA Jr, Ganmaa D, Frazier AL, et al. Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia. *Pediatrics.* 2012;130:e561–e567. doi: 10.1542/peds.2011-3029
  93. Xiao L, Xing C, Yang Z, et al. Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomised controlled trials. *Br J Nutr.* 2015;114:1026–1034. doi: 10.1017/S000711451500207X
  94. Majak P, Olszowiec-Chlebna M, Smejda K, Stelmach I. Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection. *J Allergy Clin Immunol.* 2011;127:1294–1296. doi: 10.1016/j.jaci.2010.12.016
  95. Manaseki-Holland S, Maroof Z, Bruce J, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. *Lancet.* 2012;379:1419–1427. doi: 10.1016/S0140-6736(11)61650-4
  96. Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D<sub>3</sub> supplementation for the prevention of symptomatic upper respiratory tract infections. *Epidemiol Infect.* 2009;137:1396–1404. doi: 10.1017/S0950268809002404
  97. Yusupov E, Li-Ng M, Pollack S, Yeh JK, Mikhail M, Aloia JF. Vitamin D and serum cytokines in a randomized clinical trial. *Int J Endocrinol.* 2010;2010. doi: 10.1155/2010/305054
  98. Jorde R, Witham M, Janssens W, et al. Vitamin D supplementation did not prevent influenza-like illness as diagnosed retrospectively by questionnaires in subjects participating in randomized clinical trials. *Scand J Infect Dis.* 2012;44:126–132. doi: 10.3109/00365548.2011.621446
  99. Bergman P, Norlin AC, Hansen S, et al. Vitamin D<sub>3</sub> supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. *BMJ Open.* 2012;2. doi: 10.1136/bmjopen-2012-001663
  100. Goodall EC, Granados AC, Luinstra K, et al. Vitamin D<sub>3</sub> and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial. *BMC Infect Dis.* 2014;14:273. doi: 10.1186/1471-2334-14-273
  101. Simpson S, van der Mei I, Stewart N, Blizzard L, Tettey P, Taylor B. Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT. *BMC Nutrition.* 2015;1:1–10. doi: 10.1186/2055-0928-1-7
  102. Castro M, King TS, Kunselman SJ, et al. Effect of vitamin D<sub>3</sub> on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. *JAMA.* 2014;311:2083–2091. doi: 10.1001/jama.2014.5052
  103. Martineau AR, MacLaughlin BD, Hooper RL, et al. Double-blind randomised placebo-controlled trial of bolus-dose vitamin D<sub>3</sub> supplementation in adults with asthma (ViDiAs). *Thorax.* 2015;70:451–457. doi: 10.1136/thoraxjnl-2014-206449
  104. Chandy DD, Kare J, Singh SN, et al. Effect of vitamin D supplementation, directly or via breast milk for term infants, on serum 25 hydroxyvitamin D and related biochemistry, and propensity to infection: a randomised placebo-controlled trial. *Br J Nutr.* 2016; 116:52–58. doi: 10.1017/S0007114516001756
  105. Stanciu LA, Shute J, Promwong C, Holgate ST, Djukanovic R. Increased levels of IL-4 in CD8<sup>+</sup> T cells in atopic asthma. *J Allergy Clin Immunol.* 1997;100:373–378.
  106. Stanciu LA, Roberts K, Lau LC, Coyle AJ, Johnston SL. Induction of type 2 activity in adult human CD8(+) T cells by repeated stimulation and IL-4. *Int Immunol.* 2001;13:341–348.
  107. Stanciu LA, Roberts K, Papadopoulos NG, et al. IL-4 increases type 2, but not type 1, cytokine production in CD8<sup>+</sup> T cells from mild atopic asthmatics. *Respir Res.* 2005;6:67
  108. Edfeldt K, Liu PT, Chun R, et al. T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. *Proc Natl Acad Sci U S A.* 2010;107:22593–22598. doi: 10.1073/pnas.1011624108
  109. Kalra P, Das V, Agarwal A, et al. Effect of vitamin D supplementation during pregnancy on neonatal mineral homeostasis and anthropometry of the newborn and infant. *Br J Nutr.* 2012;108:1052–1058. doi: 10.1017/S0007114511006246
  110. Goldring ST, Griffiths CJ, Martineau AR, et al. Prenatal vitamin D supplementation and child respiratory health: a randomised controlled trial. *PLoS One.* 2013;8:e66627. doi: 10.1371/journal.pone.0066627
  111. Litonjua AA, Carey VJ, Laranjo N, et al. Effect of prenatal supplementation with vitamin D on asthma or recurrent wheezing in offspring by age 3 years: the VDAART randomized clinical trial. *JAMA.* 2016;315:362–370. doi: 10.1001/jama.2015.18589
  112. Chawes BL, Bonnelykke K, Stokholm J, et al. Effect of vitamin D<sub>3</sub> supplementation during pregnancy on risk of persistent wheeze in the offspring: a randomized clinical trial. *JAMA.* 2016;315:353–361. doi: 10.1001/jama.2015.18318
  113. Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. *Lancet.* 2010;376:826–834. doi: 10.1016/S0140-6736(10)61380-3
  114. Depner M, Fuchs O, Genuneit J, et al. Clinical and epidemiologic phenotypes of childhood asthma. *Am J Respir Crit Care Med.* 2014; 189:129–138. doi: 10.1164/rccm.201307-1198OC
  115. Gold DR, Litonjua AA, Carey VJ, et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega-3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. *Contemp Clin Trials.* 2016; 47:185–195. doi: 10.1016/j.cct.2016.01.003

**How to cite this article:** Zdrengha, M. T., Makrinioti, H., Bagacean, C., Bush, A., Johnston, S. L., and Stanciu, L. A. Vitamin D modulation of innate immune responses to respiratory viral infections, *Rev Med Virol.* 2017;27:e1909. doi: 10.1002/rmv.1909.